-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hyperkalemia increases the risk of arrhythmias and death, and limits the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and mineralocorticoid receptor antagonists (MRAs)
This study is a meta-analysis of routine monitoring of serum potassium levels in randomized, double-blind, placebo-controlled randomized trials of SGLT2 inhibitors in high cardiovascular risk patients with type 2 diabetes with and without CKD.
Defined as central laboratory-determined serum potassium ≥6.
A total of 49,875 subjects were included.
SGLT2 inhibitors do not increase the risk of hypokalemia SGLT2 inhibitors do not increase the risk of hypokalemia
In conclusion, the use of SGLT2 inhibitors reduces the risk of severe hyperkalemia without increasing the risk of hypokalemia in patients with type 2 diabetes at high cardiovascular risk, with or without chronic kidney disease
The use of SGLT2 inhibitors reduces the risk of severe hyperkalemia without increasing the risk of hypokalemia in patients with type 2 diabetes at high cardiovascular risk, with or without CKD
Original source:
Original Source: Original Source:Neuen Brendon L,Oshima Megumi,Agarwal Rajiv et al.
Neuen Brendon L,Oshima Megumi,Agarwal Rajiv et al.
Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.
[J] .
Circulation, 2022, https://doi.
org/10.
1161/CIRCULATIONAHA.
121.
057736.
Leave a message here